Jeffrey Tyner

Associate Professor

Associate Professor, Knight Cancer Institute

Emailtynerj@ohsu.edu

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Jeffrey Tyner is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

9 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

2 Finished
3 Not started

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
Druker, B. & Tyner, J.
Project: Research project
Targeting PTPN11 dependent Hematologic Malignancies
Chang, B. & Tyner, J.
Project: Research project
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML
Druker, B., Tyner, J. & Agarwal, A.
Project: Research project
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven Cancer
Tyner, J.
National Institutes of Health
4/1/14 → 2/28/19
Project: Research project
ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia
Tyner, J.
National Institutes of Health
9/1/10 → 8/31/16
Project: Research project

6890 Citations
41 h-Index
132 Article
12 Review article
11 Letter
4 Comment/debate
More
- 2 Chapter
- 2 Short survey

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms
Joshi, S. K., Qian, K., Bisson, W. H., Watanabe-Smith, K., Huang, A., Bottomly, D., Traer, E., Tyner, J. W., McWeeney, S. K., Davare, M. A., Druker, B. J. & Tognon, C. E., Jun 11 2020, In: Blood. 135, 24, p. 2159-2170 12 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
Joshi, S. K., Keck, J. M., Eide, C. A., Bottomly, D., Traer, E., Tyner, J. W., McWeeney, S. K., Tognon, C. E. & Druker, B. J., Oct 1 2020, In: Leukemia. 34, 10, p. 2798-2804 7 p.
Research output: Contribution to journal › Article › peer-review

Open Access

1 Scopus citations
Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma
Anderson, A. N., McClanahan, D., Jacobs, J., Jeng, S., Vigoda, M., Blucher, A. S., Zheng, C., Yoo, Y. J., Hale, C., Ouyang, X., Clayburgh, D., Andersen, P., Tyner, J. W., Bar, A., Lucero, O. M., Leitenberger, J. J., McWeeney, S. K. & Kulesz-Martin, M., Aug 2020, In: Cold Spring Harbor Molecular Case Studies. 6, 4, a005439.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia
Damnernsawad, A., Bottomly, D., Kurtz, S. E., Eide, C. A., McWeeney, S., Tyner, J. W. & Nechiporuk, T., Dec 30 2020, In: Haematologica. Online ahead of print
Research output: Contribution to journal › Article › peer-review

Open Access
Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
Rosenberg, M. W., Watanabe-Smith, K., Tyner, J. W., Tognon, C. E., Druker, B. J. & Borate, U., Jul 21 2020, In: Oncotarget. 11, 29, p. 2807-2818 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access